Coburn Hobar

机构：Bristol-Myers Squibb (United States) · ORCID：0009-0006-5935-7997

发表论文 31 篇 · 总被引 339 次 · h-index 5

代表论文

POS0781 EFFICACY AND SAFETY OF ORAL DEUCRAVACITINIB IN PATIENTS WITH CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS: RESULTS FROM PAISLEY CLE, A GLOBAL, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL (2025 · Annals of the Rheumatic Diseases · 被引 6)
Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial (2025 · Lupus Science & Medicine · 被引 5)
Design of Two Randomized, Placebo-Controlled, Phase 3 Trials of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Systemic Lupus Erythematosus (2025 · Advances in Therapy · 被引 4)
Plain Language Summary of the PAISLEY study: deucravacitinib as a treatment for people with systemic lupus erythematosus (2024 · Expert Opinion on Investigational Drugs · 被引 3)
LP-187 Abstract withdrawn (2023 · 被引 2)
POS0543 KINETICS OF MUCOCUTANEOUS AND MUSCULOSKELETAL RESPONSES TO DEUCRAVACITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN THE PHASE 2 PAISLEY TRIAL (2024 · Annals of the Rheumatic Diseases · 被引 1)